![Darwin, Francis ed. 1887. The life and letters of Charles Darwin, including an autobiographical chapter. vol. 3. London: John Murray. Darwin, Francis ed. 1887. The life and letters of Charles Darwin, including an autobiographical chapter. vol. 3. London: John Murray.](http://darwin-online.org.uk/converted/scans/1887_Letters_F1452.3(online)/1887_Letters_F1452.3_386.jpg)
Darwin, Francis ed. 1887. The life and letters of Charles Darwin, including an autobiographical chapter. vol. 3. London: John Murray.
![Microorganisms | Free Full-Text | Phage Amplification Assay for Detection of Mycobacterial Infection: A Review Microorganisms | Free Full-Text | Phage Amplification Assay for Detection of Mycobacterial Infection: A Review](https://www.mdpi.com/microorganisms/microorganisms-09-00237/article_deploy/html/images/microorganisms-09-00237-g001.png)
Microorganisms | Free Full-Text | Phage Amplification Assay for Detection of Mycobacterial Infection: A Review
Full article: Abstracts presented at the 22nd Annual Congress of the Belgian Society of Internal Medicine, 15–16 December 2017, Dolce La Hulpe, La Hulpe, Belgium
![Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study - eBioMedicine Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study - eBioMedicine](https://www.thelancet.com/cms/attachment/7730cfb1-a463-4a8c-b9a6-69b8355aceef/gr1_lrg.jpg)
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study - eBioMedicine
![Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials - The Lancet Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials - The Lancet](https://www.thelancet.com/cms/attachment/5b4256a3-bfbc-4633-8341-2decf32ef3ff/gr2_lrg.jpg)
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials - The Lancet
![Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials - The Lancet Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials - The Lancet](https://www.thelancet.com/cms/attachment/1e76ecb5-dc8b-4b7e-a666-da6279e3503e/gr1.gif)
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials - The Lancet
![PDF) Alterations in theta-gamma coupling and sharp wave-ripple, signs of prodromal hippocampal network impairment in the TgF344-AD rat model PDF) Alterations in theta-gamma coupling and sharp wave-ripple, signs of prodromal hippocampal network impairment in the TgF344-AD rat model](https://i1.rgstatic.net/publication/369472252_Alterations_in_theta-gamma_coupling_and_sharp_wave-ripple_signs_of_prodromal_hippocampal_network_impairment_in_the_TgF344-AD_rat_model/links/641c87f9a1b72772e4209d3e/largepreview.png)